2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15321A
    Etoricoxib hydrochloride 202409-40-3
    Etoricoxib hydrochloride (MK-0663 hydrochloride) is a synthetic nonsteroidal anti-inflammatory drug with cyclooxygenase-2 inhibitory activity. Etoricoxib hydrochloride can inhibit the conversion of arachidonic acid to prostaglandins, thereby reducing inflammation and pain. Etoricoxib hydrochloride is used to inhibit osteoarthritis and has anti-inflammatory and bone remodeling effects. The formulation of etoricoxib hydrochloride is prepared by emulsion solvent evaporation technology and exhibits good cell compatibility and enhanced alkaline phosphatase activity.
    Etoricoxib hydrochloride
  • HY-15321R
    Etoricoxib (Standard) 202409-33-4
    Etoricoxib (Standard) is the analytical standard of Etoricoxib. This product is intended for research and analytical applications. Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.
    Etoricoxib (Standard)
  • HY-153234
    CD19 car circRNA-LNP
    CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.
    CD19 car circRNA-LNP
  • HY-153239
    Eltrombopag methyl ester 1246929-01-0
    Eltrombopag methyl ester is a derivative of Eltrombopag, which is a thrombopoietin (Tpo) receptor agonist, which can promote platelet production and is used in research related to specific types of thrombocytopenia.
    Eltrombopag methyl ester
  • HY-153240
    ACT-672125 1449367-94-5
    ACT-672125 is a potent CXCR3 antagonist with IC50 value of 239 nM in human blood. ACT-672125 has activity for hERG with IC50 value of 18μM. ACT-672125 can be used for the research of autoimmune diseases.
    ACT-672125
  • HY-153242
    GSK217 2748687-92-3
    GSK217 is a potent, selective, and highly soluble bromo and extraterminal domain (BET) second bromodomain (BD2) inhibitor. GSK217 can be used for the research of oncology and immune inflammation research.
    GSK217
  • HY-153247
    GSK3839919A 2081127-77-5
    GSK3839919A is a potent and allosteric HIV-1integrase inhibitor.
    GSK3839919A
  • HY-153279
    5-LOX-IN-3 1875061-47-4
    5-LOX-IN-3 (Compound 14) is a 5-Lipoxygenase inhibitor (IC50: <1 μM). 5-LOX-IN-3 can be used for research of inflammatory diseases, cancer, stroke and Alzheimer's disease.
    5-LOX-IN-3
  • HY-153330
    TNF-α-IN-10 2247720-56-3
    TNF-α-IN-10 (compound 8a) is a IL-6 and TNF-α inhibitor. TNF-α-IN-10 shows anti-inflammatory activity.
    TNF-α-IN-10
  • HY-153460
    TLR7/8/9 antagonist 2 2920729-91-3
    TLR7/8/9 antagonist 2 is an orally active TLR7/8/9 antagonist. TLR7/8/9 antagonist 2 has inhibitory activities for HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC50 values of 0.011 μM, 0.029 μM and 0,052 μM, respectively.TLR7/8/9 antagonist 2 has high bioavailability in vivo.TLR7/8/9 antagonist 2 can be used for the research of auto-inflammatory diseases such as systemic lupus erythematosus or lupus nephritis.
    TLR7/8/9 antagonist 2
  • HY-153464
    CXCR4-IN-1 2304750-48-7
    CXCR4-IN-1 (Example C5) is a CXCR4 inhibitor (IC50: 20 nM). CXCR4-IN-1 can be used for research of cancer, HIV, diabetic retinopathy, inflammation, etc.
    CXCR4-IN-1
  • HY-153471
    MOR agonist-1 2305781-14-8
    MOR agonist-1 is a MOR (μ-opioid receptor) agonist. MOR agonist-1 has good analgesic effect. MOR agonist-1 can be used for the research of pain and pain-related disorders.
    MOR agonist-1
  • HY-153479
    Aganirsen 1146887-67-3
    Aganirsen is a 25 mer DNA antisense oligonucleotide, which silences expression of insulin receptor substrate-1 (IRS-1).
    Aganirsen
  • HY-153547
    HSP90-IN-21 2521791-38-6
    HSP90-IN-21 (5e) is an antiplasmodial agent, with IC50 values of 0.04, 0.17 and 2.91 μM against erythrocytic stage of P. falciparum (Pf3D7 and PfDd2 strains), cytotoxicity of human liver hepatocellular carcinoma cell line (HepG2), respectively.
    HSP90-IN-21
  • HY-153548
    P2X2/3 modulator-1 1217483-98-1
    P2X2/3 modulator-1 (Compound 46) is a P2X2/3 modulator. P2X2/3 modulator-1 can be used in the study of pain, central nervous system disorders and inflammation.
    P2X2/3 modulator-1
  • HY-153553
    HPK1 antagonist-1 2628489-56-3
    HPK1 antagonist-1 (I-792) is an Hpk1 antagonist that can be used in the study of cancer and immune disease.
    HPK1 antagonist-1
  • HY-153564
    ROCK-IN-6 2489328-74-5
    ROCK-IN-6 is a potent and selectiveROCK2 inhibitor with an IC50 of 2.19 nM. ROCK-IN-6 is extracted from patent WO2021164351 A1, example 7, has the potential for glaucoma and retinal diseases research.
    ROCK-IN-6
  • HY-153565
    Immune cell migration-IN-1 2316683-71-1
    Immune cell migration-IN-1 (compound 2) is a potent agent to inhibit immune cell migration. Immune cell migration-IN-1 can be used for research in alleviating dry eye diseases, eczema dermatitis and psoriasis.
    Immune cell migration-IN-1
  • HY-153567
    Immune cell migration-IN-2 2260679-24-9
    Immune cell migration-IN-2 is a potent immune cell migration inhibitor with an EC50 of 13.5 nM in a T-cell adhesion assay. Immune cell migration-IN-2 is extracted from patent WO2019001171, example 11, can be used for dry-eye and other retinal diseases research. Immune cell migration-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Immune cell migration-IN-2
  • HY-153626
    Chlamydia pneumoniae-IN-1 518010-44-1
    Chlamydia pneumoniae-IN-1 (compound 55), a benzimidazole, shows high activity against the bacterium. Chlamydia pneumoniae-IN-1 has 99% inhibition of C. pneumoniae Growth at 10 μM, and has 95% inhibition effect on the viability of the host cells at 10 μM. Chlamydia pneumoniae-IN-1 inhibits the growth of the CV-6 strain with a MIC of 12.6 μM. Chlamydia pneumoniae-IN-1 has antichlamydial efficiency.
    Chlamydia pneumoniae-IN-1
Cat. No. Product Name / Synonyms Application Reactivity